-
Gene Tektronox anti-TIGIT antibody Tiragolumab has been identified by the FDA as a breakthrough therapy
Time of Update: 2021-01-16
of THE CITYSCAPE, published at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO), showed an improvement in the overall remission rate (ORR of 37% vs. 21% of the risk of disease deterioration or death (no progression survival PFS
-
BCMA Target Development: CAR-T, Dual Resistance, Antibody Association Drugs Who Will Win First?
Time of Update: 2021-01-16
The immunotherapy currently developed for BCMA targets is divided into three main categories: chime antigen-subject T-cell therapy (CAR-T, new-based/bluebird biology, Johnson and Johnson-Legend), dual-specific antibodies (BsAb, represented by Amgen), and antibody drug couples (represented by ADC, GSK).
-
Journal of Science: Relationship between natural A-beta antibodies and alzheimer's brain amyloid and cognitive function
Time of Update: 2021-01-16
Alzheimer's disease (AD), commonly known as Alzheimer's disease, is a de-detox. early stages, AD is characterized by aggregation and memory loss of amyloid β (A beta) and tau proteins in the brain. 15-20 years before AD attacks, toxic β
-
Pioneering PharmaceuticalSALK Antibodies and Opdivo Second-Line Treatment HCC Data Bright: Objective Remission Rate 40%
Time of Update: 2021-01-16
American Society of Clinical Oncology (ASCO GI) Gastrointestinal Oncology Symposium (ASCO GI). results show that the efficacy of combination therapy is encouraging and safe. 2021 ASCO GI will be held from January 15-17, 2021 local time
-
Preparation of Immunogens and Production of Antibodies
Time of Update: 2021-01-16
Methods used in conventional viral purification and molecular cloning and expression of target viral proteins to obtain antigens for immunization are presented.
-
And Platinum Pharmaceuticals jointly announced the launch of AbbVie's new Coronary Antibody Phase 1 clinical trial
Time of Update: 2021-01-15
Phase I clinical trials will be a randomized, double-blind, placebo-controlled study designed to assess the safety, pharmacodynamics, and pharmacodynamics of ABBV-47D11 in a single dose climb in COVID-19 adult hospitalized populations.
-
Today Rongchang bio-anti-HER2 antibody association drugs are to be included in the breakthrough treatment varieties
Time of Update: 2021-01-15
Rongchang Bio plans to submit to China's State Drug Administration in the first half of 2021 vidicido single anti-treatment of urethra skin cancer new drug market applications.
-
Lancet Oncol: CD40 astrogenic monoclonal antibody APX005M combined chemotherapy to treat metastatic pancreatic cancer
Time of Update: 2021-01-14
the study was designed to assess the safety of APX005M (sotigalimab) and Gissytabin combined nab-yew alcohol and or non-navutamol to treat patients with pancreatic cancer to determine the recommended phase 2 dose.
-
sub-antibody MK-4166 for the treatment of advanced solid tumors
Time of Update: 2021-01-14
A: Tumor size changes in extended cohort patients; B:ICI initial treatment patients' response and duration in dose incremental cohorts (n-45), the combined treatment group had a period of objective remission (ORR 2.2%).
-
Dual-specific antibody TR009 / ABL001 targeting VEGF / DLL4 treats gastroesic tumors with encouraging preclinical results
Time of Update: 2021-01-14
in the Notch path, Delta-like liage 4 (DLL4) plays an important role in affecting tumor angiogenesic angiogenesy, which inhibits the formation of new blood vessels and promotes the maturation of new blood vessels.
-
U.S. Kidney Care (USRC) will treat COVID-19 patients with single clone antibodies (Bamlanivimab) at dialysis clinics
Time of Update: 2021-01-13
USRC obtained Bamlanivimab through operation Warp Speed and Project SPEED programs and will use the drug in dialysis clinics for patients with mild to moderate COVID-19.
-
Production of Monoclonal Antibodies to Plant Pathogens
Time of Update: 2021-01-13
The use of monoclonal antibodies in plant pathology has improved the quality and specificity of detection methods for diseases. Hybridoma technology allows the limitless production of highly specific antibodies which can be used to identify pathogens to the species or even sub-species level.
-
Antibody "cocktail" therapy for COVID-19 inpatients: positive clinical data have been obtained
Time of Update: 2021-01-13
In serum-negative patients, the antibody "cocktail" reduced the daily viral load by -0.54 log10 copies/mL on the 7th day and by -0.63 log10 copies/mL on the 11th day (p -0.002).
-
Knocking out the autophagy gene Rb1cc1 is expected to improve the efficacy of PD-1 antibodies, new research suggests
Time of Update: 2021-01-12
researchers knocked out three key autophagy genes, Rb1cc1, Atg9a and Atg12, and found that tumor cells became sensitive to T-cell killing.
-
Prevention of Type 1 Diabetes Innovative CD3 antibodies are eligible for FDA Priority Review
Time of Update: 2021-01-12
As a chronic autoimmune disease, the immune system of people with type 1 diabetes mistakenly attacks their islet β cells, causing the β cells to gradually impair and die, and eventually the patient needs to rely on external insulin for treatment
-
Nature important finding: PD-1 antibody "new partner" - PCSK9 inhibitor
Time of Update: 2021-01-10
cells. the PCSK9 gene also greatly enhances the efficacy of PD-1 antibodies. addition, studies have confirmed that in cancer mouse models, approved PCSK9-listed antibodies and PD-1 antibodies have developed synergies in inhibiting tumor
-
The injection of PD-L1 antibody KN035 submitted an application for the listing of a new drug in China
Time of Update: 2021-01-09
application is based on KN035 single-drug treatment of MSI-H/dMMR advanced solid tumor phase 2 key clinical trial data.
-
Characterization and Applications of Plant-Derived Recombinant Antibodies
Time of Update: 2021-01-09
Expression of foreign proteins in plants has become a standard technique in plant molecular biology. Various plant species have been used to produce mammalian proteins, such as human interferon ( 1 ) and serum albumin ( 2
-
CD30/CD16A dual-specific teteal antibody combination K drug therapy R/R HL is better than single drug therapy
Time of Update: 2021-01-08
of Keytruda single-drug therapy in similar patient groups: in the KEYNOTE-087 study, Keytruda single-drug treatment had ORR of 69% and CR of 22.4%. the study, AFM13 and Keytruda were well-to-do and had similar safety requirements to those known
-
Antibodies are sequenced from the beginning
Time of Update: 2021-01-07
Typically, we use a variety of enzymes with different cutting sequences to break down antibodies, ensuring that each area of the antibody produces several overlapping peptides.
